This new surfactant contains 76% of phosphatidylcholine, 6–8% of phosphatidylethanolamine, 6% of phosphatidylinositol + phosphatidylserine, and 4–6% of sphingomyelin; 30–35% of the ...
Discover Ipsen SA's patented liposomal formulation of irinotecan, designed for enhanced stability and efficacy in cancer treatment. Learn about its innovative composition and benefits.